Cell Therapy Catapult Signs Major Development Agreement with Asterias Biotherapeutics Inc. The Cell Therapy Catapult announced the signing of an agreement with Asterias Biotherapeutics Inc. The agreement engages the Cell Therapy Catapult to advance development of a large scale manufacturing processes for AST-VAC2, Asterias’ allogeneic dendritic cell immunotherapy. [Cell Therapy Catapult] Press Release Generex Announces Memorandum of Understanding in Respect of a Phase II Clinical Trial for the Antigen Express Prostate Cancer Vaccine Generex Biotechnology Corporation announced that its wholly-owned immunotherapeutics subsidiary, Antigen Express, Inc., has entered into a memorandum of understanding with CompanDX Ltd. to conduct a Phase II clinical trial of the Antigen Express proprietary prostate cancer vaccine. [Generex Biotechnology Corporation] Press Release Immatics and UTHealth to Collaborate on Cellular Manufacturing for Phase I Clinical Trials Immatics US, Inc. and The University of Texas Health Science Center at Houston (UTHealth) will collaborate on cellular manufacturing for adoptive cellular therapy clinical trials. [The University of Texas Health Science Center at Houston] Press Release Incyte and Merck Expand Clinical Collaboration to Include Phase III Study Investigating the Combination of Epacadostat with Keytruda® (Pembrolizumab) as First-Line Treatment for Advanced Melanoma Incyte Corporation and Merck announced the expansion of the companies’ ongoing clinical collaboration to include a Phase III study evaluating the combination of epacadostat, Incyte’s investigational selective IDO1 inhibitor, with Keytruda® (pembrolizumab), Merck’s anti-PD-1 therapy, as first-line treatment for patients with advanced or metastatic melanoma. [Merck & Co., Inc.] Press Release HemaCare Committed to Cell Therapy Research through Strategic Agreements HemaCare Corporation has expanded its growing cell therapy client portfolio through several supply agreements with Cellectis, Dendreon, and Sotio. Under the agreements, HemaCare provides process development support and supplies high-quality cGMP and research-grade biological material for use in cell therapy research and development of commercially available products, including Provenge®. [HemaCare Corporation (Business Wire)] Press Release German and US Partners Join Forces in Stem Cell Research to Accelerate Development of New Therapies Researchers at The Scripps Research Institute, and two German institutes, the Center for Integrated Psychiatry Kiel and the Fraunhofer Institute for Molecular Biology and Applied Ecology IME, have announced a partnership to advance the quality control of human stem cells. [The Scripps Research Institute] Press Release Medifocus Inc. Announces Exclusive Agreement with Major Academic Medical Center to License Technology to Develop Heat-Activated and Tumor-Targeted Immunotherapy and Gene Therapy Medifocus, Inc. announced that the company has formally entered into an exclusive license agreement with Duke University regarding heat-activated and tumor-targeted immunotherapy and gene therapy. [Medifocus, Inc. (Marketwired L.P.)] Press Release RXi Pharmaceuticals Bolsters Protection for Its Novel Self-Delivering RNAi Platform with Notice of Allowance from USPTO RXi Pharmaceuticals Corporation announced that it has been granted a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for both the composition and methods of use of RXi’s self-delivering platform technology. [RXi Pharmaceuticals Corporation] Press Release OncoQR’s Breast Cancer Vaccine Successfully Completes Pre-Clinical Proof-of-Concept Study OncoQR ML announced that its breast cancer vaccine candidate OQR200 has successfully completed a proof-of-concept study in non-human primates. The vaccine elicited the expression of very high levels of polyclonal antibodies targeting multiple epitopes on Her2/neu. [OncoQR ML (B3C Group GmbH)] Press Release Celsion Announces Impressive Preclinical Data for Its GEN-1 IL-12 Immunotherapy in Combination with Avastin® and Doxil® for Ovarian Cancer Results from the comprehensive studies confirmed remarkable initial GEN-1 + Avastin® findings and show convincingly that GEN-1 when combined with Avastin® and Doxil®, standard of care for platinum resistant patients, demonstrated a greater than 98% reduction in tumor burden when compared to the untreated control group. [Celsion Corporation] Press Release Human Longevity, Inc. Launches the Health Nucleus, a Comprehensive and Personalized Health Platform for Individuals Human Longevity, Inc. announced the launch of the company’s first Health Nucleus™, a genomic powered clinical research project that has the potential to transform healthcare. [Human Longevity, Inc.] Press Release Cell Therapy Ltd. to Submit Heartcel™ for Conditional Marketing Authorization Post Meeting with the European Medicines Agency Cell Therapy Ltd. announced that, following a pre-submission meeting with the European Medicines Agency, CTL will begin the application process for a conditional marketing authorization for Heartcel™, the first allogeneic stem cell therapy to regenerate the human heart, in Europe. [Cell Therapy Ltd.] Press Release |